Response to Andrew Dunning's comment on 'evaluating a surrogate endpoint at three levels, with application to vaccine development'

Stat Med. 2009 Feb 15;28(4):716-9. doi: 10.1002/sim.3503.

Abstract

In replying to Andrew Dunning’s helpful letter, we endeavor to clarify the value of incorporating baseline participant predictors of the potential surrogate endpoint and of the clinical endpoint into the evaluation of a surrogate endpoint. Such baseline predictors are useful for the evaluation of surrogates defined within each of the statistical and principal surrogate frameworks, which are complementary.

Publication types

  • Comment
  • Research Support, N.I.H., Extramural

MeSH terms

  • Biomarkers*
  • Biometry / methods*
  • Data Interpretation, Statistical
  • Humans
  • Models, Statistical*
  • Randomized Controlled Trials as Topic / methods*
  • Vaccines / pharmacology

Substances

  • Biomarkers
  • Vaccines